Martin Tami Tillotson
SEC CIK 1539494 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| SUPN | SUPERNUS PHARMACEUTICALS, INC. | SVP, Regulatory Affairs | 87.4K | — | $989.5K | 17 | 2022-08-04 | 2024-02-23 |
Most active insiders at SUPN, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Khattar Jack A. | Pres, CEO, Dir | — | $7.72M |
| 2 | Bhatt Padmanabh P. | CSO, SVP of IP | — | $5.42M |
| 3 | NEWHALL CHARLES W III | Dir | — | $1.27M |
| 4 | Mottola Frank | SVP, Chief Tech. Ops. Off | — | $1.10M |
| 5 | GEMAYEL GEORGES | Dir | — | $1.00M |
| 6 | Horich William Todd | SVP, Commercial Ops | — | $483.8K |
| 7 | Hudson Frederick M. | Dir | — | $271.7K |
| 8 | Sensenig Bethany | Dir | — | $228.3K |
| 9 | Rubin Jonathan | SVP, Chief Medical Off | — | — |
| 10 | Barlow Carrolee | Dir | — | — |
Martin Tami Tillotson made no open-market trades at SUPN in the last 12 months.
Transactions 17
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-02-27 | 2024-02-23 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | A - Grant | $0.00 | +1,250 | 87.4K | +1% | $0 |
| D | 2024-02-27 | 2024-02-23 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | F - Tax | $29.06 | -485 | 86.9K | -0.6% | -$14.1K |
| D | 2024-02-26 | 2024-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | F - Tax | $27.94 | -246 | 86.2K | -0.3% | -$6,873 |
| D | 2024-02-26 | 2024-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | A - Grant | $0.00 | +750 | 86.4K | +0.9% | $0 |
| D | 2024-01-12 | 2024-01-10 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | S - Sale+OE | $27.91 | -8,000 | 85.7K | -9% | -$223.3K |
| D | 2024-01-12 | 2024-01-10 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | M - OptEx | $9.24 | +8,000 | 93.7K | +9% | +$73.9K |
| D | 2023-09-01 | 2023-08-30 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | M - OptEx | $23.99 | +8,100 | 93.3K | +10% | +$194.3K |
| D | 2023-09-01 | 2023-08-30 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | S - Sale+OE | $32.00 | -8,100 | 85.2K | -9% | -$259.2K |
| 2023-08-29 | 2023-08-25 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | S - Sale | $31.59 | -5,135 | 85.2K | -6% | -$162.2K | |
| DA | 2023-04-12 | 2023-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | F - Tax | $38.57 | -289 | 90.0K | -0.3% | -$11.1K |
| DA | 2023-04-12 | 2023-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | A - Grant | $0.00 | +750 | 90.3K | +0.8% | $0 |
| D | 2023-02-24 | 2023-02-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | A - Grant | $0.00 | +750 | 90.3K | +0.8% | $0 |
| D | 2023-02-21 | 2023-02-16 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | M - OptEx | $0.00 | +1,500 | 88.7K | +2% | $0 |
| D | 2022-08-23 | 2022-08-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | M - OptEx | $7.90 | +5,000 | 92.2K | +6% | +$39.5K |
| D | 2022-08-23 | 2022-08-22 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | S - Sale+OE | $35.98 | -5,000 | 87.2K | -5% | -$179.9K |
| D | 2022-08-05 | 2022-08-04 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | S - Sale+OE | $32.98 | -5,000 | 87.2K | -5% | -$164.9K |
| D | 2022-08-05 | 2022-08-04 | SUPN | SUPERNUS PHARMACEUTICALS, INC. | Martin Tami Tillotson | SVP, Regulatory Affairs | M - OptEx | $7.90 | +5,000 | 92.2K | +6% | +$39.5K |
Purchase Sale Sale after option exercise All abbreviations